Cohen Mitchell B, Giannella Ralph A, Bean Judy, Taylor David N, Parker Susan, Hoeper Amy, Wowk Stephen, Hawkins Jennifer, Kochi Sims K, Schiff Gilbert, Killeen Kevin P
Division of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA.
Infect Immun. 2002 Apr;70(4):1965-70. doi: 10.1128/IAI.70.4.1965-1970.2002.
Peru-15 is a live attenuated oral vaccine derived from a Vibrio cholerae O1 El Tor Inaba strain by a series of deletions and modifications, including deletion of the entire CT genetic element. Peru-15 is also a stable, motility-defective strain and is unable to recombine with homologous DNA. We wished to determine whether a single oral dose of Peru-15 was safe and immunogenic and whether it would provide significant protection against moderate and severe diarrhea in a randomized, double-blind, placebo-controlled human volunteer cholera challenge model. A total of 59 volunteers were randomly allocated to groups to receive either 2 x 10(8) CFU of reconstituted, lyophilized Peru-15 vaccine diluted in CeraVacx buffer or placebo (CeraVacx buffer alone). Approximately 3 months after vaccination, 36 of these volunteers were challenged with approximately 10(5) CFU of virulent V. cholerae O1 El Tor Inaba strain N16961, prepared from a standardized frozen inoculum. Among vaccinees, 98% showed at least a fourfold increase in vibriocidal antibody titers. After challenge, 5 (42%) of the 12 placebo recipients and none (0%) of the 24 vaccinees had moderate or severe diarrhea (> or = 3,000 g of diarrheal stool) (P = 0.002; protective efficacy, 100%; lower one-sided 95% confidence limit, 75%). A total of 7 (58%) of the 12 placebo recipients and 1 (4%) of the 24 vaccinees had any diarrhea (P < 0.001; protective efficacy, 93%; lower one-sided 95% confidence limit, 62%). The total number of diarrheal stools, weight of diarrheal stools, incidence of fever, and peak stool V. cholerae excretion among vaccinees were all significantly lower than in placebo recipients. Peru-15 is a well-tolerated and immunogenic oral cholera vaccine that affords protective efficacy against life-threatening cholera diarrhea in a human volunteer challenge model. This vaccine may therefore be a safe and effective tool to prevent cholera in travelers and is a strong candidate for further evaluation to prevent cholera in an area where cholera is endemic.
秘鲁 - 15是一种口服减毒活疫苗,由霍乱弧菌O1埃尔托稻叶菌株经一系列缺失和修饰后获得,包括删除整个CT遗传元件。秘鲁 - 15也是一种稳定的、运动缺陷型菌株,无法与同源DNA重组。我们希望确定单剂量口服秘鲁 - 15是否安全且具有免疫原性,以及在随机、双盲、安慰剂对照的人类志愿者霍乱攻击模型中,它是否能为中度和重度腹泻提供显著保护。总共59名志愿者被随机分组,分别接受用CeraVacx缓冲液稀释的2×10⁸CFU冻干重组秘鲁 - 15疫苗或安慰剂(仅CeraVacx缓冲液)。接种疫苗约3个月后,其中36名志愿者受到约10⁵CFU由标准化冷冻接种物制备的强毒霍乱弧菌O1埃尔托稻叶菌株N16961的攻击。在接种疫苗者中,98%的人杀弧菌抗体滴度至少升高了四倍。攻击后,12名安慰剂接受者中有5人(42%)出现中度或重度腹泻(腹泻粪便≥3000克),而24名接种疫苗者中无人(0%)出现此类情况(P = 0.002;保护效力为100%;单侧95%置信下限为75%)。12名安慰剂接受者中有7人(58%)出现任何腹泻,24名接种疫苗者中有1人(4%)出现腹泻(P < 0.001;保护效力为93%;单侧95%置信下限为62%)。接种疫苗者的腹泻粪便总数、腹泻粪便重量、发热发生率以及粪便中霍乱弧菌排泄峰值均显著低于安慰剂接受者。秘鲁 - 15是一种耐受性良好且具有免疫原性的口服霍乱疫苗,在人类志愿者攻击模型中对危及生命的霍乱腹泻具有保护效力。因此,这种疫苗可能是预防旅行者霍乱的安全有效工具,并且是在霍乱流行地区预防霍乱进一步评估的有力候选疫苗。